Dateline Washington

Coorsh, Richard
December 1998
Consumers' Research Magazine;Dec98, Vol. 81 Issue 12, p6
Introduces Enbrel, a genetically engineered drug approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis.


Related Articles

  • Warning issued on RA drug. Maudlin, Robert K. // Modern Medicine;Jun99, Vol. 67 Issue 6, p51 

    Focuses on the advice of the United States Food and Drug Administration regarding the use of etanercept, an approved treatment for moderate to severe rheumatoid arthritis. Warning on the label when the drug was originally approved; Advice for physicians when considering prescribing etanercept...

  • Rheumatoid arthritis drugs show promise.  // Mayo Clinic Health Letter;Jan1999, Vol. 17 Issue 1, p4 

    Broadcasts the approval of the Food and Drug Administration for two drugs, etanercept and leflunomide for the treatment of rheumatoid arthritis. Drug composition; Dosage.

  • Hitting RA head-on. Portyansky, Elena // Drug Topics;9/7/98, Vol. 142 Issue 17, p21 

    Reports that the disease-modifying antiheumatic drug (DMARD), Arava (leflunomide), for treatment of active rheumatoid arthritis (RA) in adults has been recommended for approval by a Food and Drug Administration advisory committee in the United States. Benefits of the drug; Uses of the drug if...

  • FDA approves rheumatoid arthritis drug.  // Dermatology Times;Jan2002, Vol. 23 Issue 1, p14 

    Announces that the United States Food and Drug Administration has given its approval for anakinra, a drug for the treatment of rheumatoid arthritis for patients who have failed one or more disease-modifying antirheumatic drugs. Drug background.

  • New Treatment Device for Rheumatoid Arthritis. Rose, Verna L. // American Family Physician;5/1/1999, Vol. 59 Issue 9, p2656 

    Reports that the United States Food and Drug Administration has approved Prosorba, a therapeutic device for patients with rheumatoid arthritis. How the device works; Results from clinical trials.

  • When to use the new rheumatologic drugs.  // Patient Care;10/15/1999, Vol. 33 Issue 16, p106 

    Tackles the long-term benefits and risks of using rheumatologic drugs that have been introduced in the United States. Patients afflicted with rheumatoid arthritis; Use of methotrexate for treating patients with severe disease; Disease-modifying antirheumatic drugs called leflunomide and...

  • Genentech submits sBLA for rheumatoid arthritis drug.  // PharmaWatch: Biotechnology;May2010, Vol. 9 Issue 5, p10 

    The article reports on the submission of a supplemental biologics license application (sBLA) by Genentech Inc. to the Food & Drug Administration (FDA) for Actemra in the U.S. It states that Actemra prevents structural joint damage and improves physical function in adults with active rheumatoid...

  • New indication for anakinra.  // Drug Topics;9/15/2003, Vol. 147 Issue 18, p7 

    Reports on the United States Food and Drug Administration's approval of anakinra for slowing the progression of structural damage in moderately to severely active rheumatoid arthritis in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs.

  • UCB: Cimzia's indication expansion hindered by FDA.  // PharmaWatch: Monthly Review;Feb2009, Vol. 8 Issue 2, p17 

    The article reports that UCB Inc. has received a letter from the U.S. Food and Drug Administration (FDA) delaying the approval of its Cimzia (certolizumab), a treatment for rheumatoid arthritis. The letter asks UCB to provide new safety update with all clinical data of Cimzia as a prerequisite...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics